Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy.
Cleare, A J, Miell, J, Heap, E et al. · The Journal of clinical endocrinology and metabolism · 2001 · DOI
Quick Summary
This study examined whether ME/CFS patients have problems with their stress hormone system (called the HPA axis) and whether a low dose of the steroid hormone hydrocortisone could help. Researchers found that ME/CFS patients had lower levels of cortisol (a stress hormone) in their urine and a reduced response to certain hormone challenges, suggesting their adrenal glands may not be producing enough cortisol. When some patients received hydrocortisone treatment, their fatigue improved and their hormone responses normalized.
Why It Matters
This study is important because it identifies a potentially treatable endocrine abnormality (reduced adrenal cortisol output) in ME/CFS and demonstrates that low-dose hydrocortisone can restore hormone function and reduce fatigue in a subset of patients. Understanding the HPA axis abnormality helps explain some of ME/CFS's physiological basis and may guide personalized treatment approaches.
Observed Findings
ME/CFS patients had significantly lower 24-hour urinary free cortisol compared to healthy controls.
Cortisol responses to CRH and D-fenfluramine were blunted in ME/CFS patients when ACTH responses were controlled for.
ACTH responses to all challenge tests (CRH, insulin stress, D-fenfluramine) were similar between ME/CFS patients and controls, suggesting intact pituitary function.
Low-dose hydrocortisone treatment increased 24-hour urinary cortisol levels across all treated patients.
In patients who responded clinically to hydrocortisone (fatigue reduced to median population level or lower), cortisol responses to CRH were significantly increased and the previously blunted response was reversed.
Inferred Conclusions
The hypocortisolism observed in ME/CFS appears to be secondary to reduced adrenal gland output rather than central (brain-level) HPA axis dysfunction, since pituitary ACTH responses are intact.
Low-dose hydrocortisone therapy can normalize cortisol responses and improve fatigue in a subset of ME/CFS patients, suggesting therapeutic potential for those with documented HPA axis abnormalities.
The biochemical normalization of cortisol responses in clinical responders indicates that HPA axis dysfunction in ME/CFS may be partially reversible with appropriate hormone augmentation.
Remaining Questions
Why do only some ME/CFS patients respond clinically to hydrocortisone, and what baseline characteristics predict responders versus non-responders?
What This Study Does Not Prove
This study does not prove that HPA axis dysfunction causes ME/CFS—the abnormality could be secondary to other disease mechanisms. It also does not demonstrate that all ME/CFS patients will benefit from hydrocortisone, nor does it address long-term safety and efficacy of this treatment. The mechanism explaining why some patients respond and others do not remains unknown.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
What is the mechanism of the adrenal hyporesponsiveness—is it intrinsic adrenal pathology, reduced ACTH signaling sensitivity, or secondary inhibition?
What are the long-term safety and efficacy outcomes of low-dose hydrocortisone treatment in ME/CFS beyond the 28-day treatment periods studied?
Does HPA axis dysfunction represent a primary disease driver or a secondary consequence of other ME/CFS pathophysiology?